Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.88
- Piotroski Score 4.00
- Grade Sell
- Symbol (RDUS)
- Company Radius Health, Inc.
- Price $17.66
- Changes Percentage (-0.39%)
- Change -$0.07
- Day Low $17.50
- Day High $18.14
- Year High $31.70
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
- Last Earnings 10/22/2024
- Ex-Dividend for 5/16 Dividend 11/12/2024
- Dividend Payable 11/26/2024
- Today N/A
- Next Earnings (Estimated) 01/02/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.26
- Trailing P/E Ratio -7.04
- Forward P/E Ratio -7.04
- P/E Growth -7.04
- Net Income $-25,791,000
Income Statement
Quarterly
Annual
Latest News of RDUS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CNN Bans Ryan Girdusky After 'Beeper' Remark to Mehdi Hasan
Conservative commentator Ryan Girdusky was banned from CNN after making remarks implying guest Mehdi Hasan was a member of Hezbollah. CNN stated there is no room for racism or bigotry on their network...
By The New York Times | 2 weeks ago -
CNN bans panelist Ryan Girdusky after 'unacceptable' comment hurled at Mehdi Hasan
During a heated exchange on a talk show, conservative Ryan Girdusky made a controversial comment towards Hasan, founder of Zeteo News. The host and panelists condemned the remark, leading to Girdusky'...
By USA Today | 2 weeks ago -
CNN Bans Conservative Ryan Girdusky After Comment About Muslim Panelist's Beeper Going Off
Conservative commentator Ryan Girdusky was banned from CNN after implying that Mehdi Hasan was a Hezbollah member. CNN stated there's no room for bigotry. Girdusky criticized CNN for not allowing joke...
By Forbes | 2 weeks ago
